4 completed, 2 recruiting, 2 terminated, 2 unknown. 8 Phase 2, 7 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 2, Recruiting 2, Terminated 2, Unknown 1, Withdrawn 1 |
| Phase 1 | 7 | Completed 3, Terminated 2, Unknown 1, Withdrawn 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow IPH2201: new trials by email Literature Review of IPH2201 trials Research Report on IPH2201
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study Biospecimen Collection, Ceralasertib, Computed Tomography - Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype | Phase 2 | Recruiting | SWOG Cancer Research Network | 900 | 2025-11-06 | 2026-03-30 |
| Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer Durvalumab, Oleclumab, Monalizumab - Non-small Cell Lung Cancer | Phase 2 | Recruiting | AstraZeneca | 630 | 2022-04-14 | 2026-10-21 |
| Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer Monalizumab, Cetuximab, Placebo - Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Active not recruiting | AstraZeneca | 370 | 2020-10-02 | 2026-09-09 |
| Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial Accelerated Hypofractionated Radiation Therapy, Biospecimen Collection, Computed Tomography - Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2019-10-28 | 2025-09-23 |
| Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer Durvalumab, Oleclumab, Monalizumab - Resectable, Early-stage | Phase 2 | Completed | MedImmune LLC | 84 | 2019-03-08 | 2022-02-24 |
| Biomarker-based Study in R/M SCCHN Afatinib, Palbociclib, standard of care - Carcinoma, Squamous Cell of Head and Neck | Phase 2 | Unknown | European Organisation for Research and Treatment of Cancer - EORTC | 340 | 2017-11-16 | 2023-11-03 |
| Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA Monalizumab, Oxaliplatin, 5-Fluorouracil - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 / Phase 2 | Withdrawn | Jules Bordet Institute | 2017-07-20 | 2017-12-19 | |
| Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation Monalizumab - Hematologic Malignancies | Phase 1 | Unknown | Institut Paoli-Calmettes | 18 | 2016-11-28 | 2018-09-19 |
| Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Monalizumab, Cetuximab, Anti-PD(L)1 - Head and Neck Neoplasms | Phase 1 / Phase 2 | Completed | Innate Pharma | 143 | 2015-12-01 | 2023-05-12 |
| Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL monalizumab - Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | Innate Pharma | 22 | 2015-11-09 | 2019-12-17 |
| A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies IPH2201 - Gynecologic Cancer | Phase 1 | Completed | Canadian Cancer Trials Group | 59 | 2015-09-17 | 2023-08-04 |
| Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity IPH2201, Standard Surgery, Postsurgical Adjuvant Therapy - Squamous Cell Carcinoma of the Oral Cavity | Phase 1 / Phase 2 | Terminated | Innate Pharma | 3 | 2014-12-01 | 2017-01-04 |
Squamous Cell Carcinoma of Head and Neck (3) · Carcinoma, Non-Small-Cell Lung (2) · Head and Neck Neoplasms (2) · Lung Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Esophageal Squamous Cell Carcinoma (1) · Hematologic Neoplasms (1) · Laryngeal Diseases (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Neoplasms (1) · Small Cell Lung Carcinoma (1)
Innate Pharma (3) · AstraZeneca (2) · Canadian Cancer Trials Group (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Institut Paoli-Calmettes (1) · Jules Bordet Institute (1) · MedImmune LLC (1) · National Cancer Institute (NCI) (1) · SWOG Cancer Research Network (1)
United States (7) · France (6) · Spain (5) · Belgium (4) · Canada (4) · Italy (4) · Portugal (3) · Germany (2) · South Korea (2) · Switzerland (2) · Taiwan (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Austria (1)
Amelie Deleporte, Physician (1) · Anna Tinker (1) · Anne C Chiang (1) · Dario Ruscica, MD (1) · Hal Hirte (1) · Kerry A Rogers, MD (1) · Roger B Cohen, MD (1) · Steven H Lin (1) · Tina Cascone, MD (1)
PMID 29700172, PMID 30307465, PMID 31308062, PMID 36852723, PMID 37707791, PMID 40450142, PMID 41151963
2014 (1), 2016 (1), 2017 (1), 2019 (1), 2023 (1), U10CA180868 (1), U10CA180888 (1)